Adam PJ, Terrett JA, Steers G, Stockwin L, Loader JA, Fletcher GC, Lu LS, Leach BI, Mason S, Stamps AC, Boyd RS, Pezzella F, Gatter KC, Harris AL (2006) CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. Br J Cancer 95(3):298-306. doi: 10.1038/sj.bjc.6603222
Summary: Renal cell carcinoma (RCC) is usually resistant to chemotherapy. Using a proteomics approach, the authors found a potential target for immunotherapy in RCC. An antibody against CD70, a type II transmembrane receptor, was combined with Hum-ZAP (Cat. #IT-22). The complex was then added to an RCC-derived cell-line in vitro. The aCD70/Hum-ZAP complex demonstrated significant killing at several different concentrations. This work suggests that CD70 is a potential target antigen for RCC therapy.
Related Products: Hum-ZAP (Cat. #IT-22)